(S)-Enzaplatovir

Cat. No.: HY-109004A CAS No.: 1323077-88-8 Molecular Formula: $C_{20}H_{19}N_5O_3$ Molecular Weight: 377.4 RSV Target:

Pathway: Anti-infection

Storage: Powder -20°C 3 years

2 years

-80°C In solvent 6 months

> -20°C 1 month

Product Data Sheet

SOLVENT & SOLUBILITY

In Vitro

DMSO: 200 mg/mL (529.94 mM; Need ultrasonic)

Preparing Stock Solutions	Solvent Mass Concentration	1 mg	5 mg	10 mg
	1 mM	2.6497 mL	13.2485 mL	26.4971 mL
	5 mM	0.5299 mL	2.6497 mL	5.2994 mL
	10 mM	0.2650 mL	1.3249 mL	2.6497 mL

Please refer to the solubility information to select the appropriate solvent.

In Vivo

- 1. Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline Solubility: ≥ 5 mg/mL (13.25 mM); Clear solution
- 2. Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline) Solubility: ≥ 5 mg/mL (13.25 mM); Clear solution
- 3. Add each solvent one by one: 10% DMSO >> 90% corn oil Solubility: ≥ 5 mg/mL (13.25 mM); Clear solution

BIOLOGICAL ACTIVITY

Description

(S)-Enzaplatovir ((S)-BTA-C585) is the S-enantiomer of Enzaplatovir. (S)-Enzaplatovir shows antiviral activities with an EC50 of 56 nM for respiratory syncytial viral (RSV) (patent WO2011094823A1 compound 77)^[1].

REFERENCES

1]. Jeffrey Peter Mitchell, et al. Compou	unds for treating respiratory syncytial vi	rus infections. WO2011094823A1	
Cauti	on: Product has not been fully vali	dated for modical applications. E	or recearch use only
Tet: 60	09-228-6898 Fax: 609-228 Address: 1 Deer Park Dr, Sui	E-mail: tech@Moite Q, Monmouth Junction, NJ 088	edChemExpress.com 52, USA

Page 2 of 2 www.MedChemExpress.com